Can nicotinamide riboside contribute to NAD+ production in eukaryotes even if the main pathway uses nicotinic acid mononucleotide?
What the Evidence Shows
What we've found so far is that nicotinamide riboside can contribute to NAD+ production in eukaryotes, even if the main pathway involves nicotinic acid mononucleotide [1]. Our analysis of the available research shows that the body has multiple ways to produce NAD+, and one of those ways includes using nicotinamide riboside as a building block [1]. This suggests that NAD+ synthesis isn’t limited to just one route — alternative pathways exist and can be used [1].
The evidence we've reviewed leans toward the idea that cells can use different starting materials to make NAD+, depending on what’s available. Nicotinamide riboside appears to be one of those usable precursors . While the main pathway may rely on nicotinic acid mononucleotide, the presence of parallel routes means the system is flexible . This redundancy could help maintain NAD+ levels under varying conditions.
We don’t yet know how much nicotinamide riboside contributes compared to other precursors, or how this might vary between tissues or health states. But based on what we've reviewed so far, the body’s ability to use multiple inputs for NAD+ production is supported by the evidence .
Practical takeaway: Your body can use different building blocks to make NAD+, and nicotinamide riboside is one of them — even if other pathways are more dominant.